Biomea Fusion Inc at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is BioMarin fusion. And presenting on behalf of the company is CEO, Tom Butler, there Q&A session after the presentation. So just raise your hand, we'll get a mike over to you and for folks for Andrew folks tuning in via the webcast. You can also submit questions via the portal. With that, Tom, thanks for joining us today.
Thank you very much, Eric, and good morning, everybody. Exciting to be here and kick off the 2024 year at the JPMorgan conference, and I'll be making forward-looking statements during this presentation. So please note our mission we aim to cure is at the center of everything we do at the Company and we believe that our approach may lead to significant improvement and extension of life for our patients. And that's really the driving force behind our efforts. And we had a very successful 2023, really reading out the first clinical data in both oncology and diabetes for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |